白蛋白抑制肝素结合蛋白是否是感染性休克中白蛋白疗效的机制?
该研究包含体外人内皮细胞和肾小管上皮细胞模型,以及感染性休克观察队列(Vasopressin and Septic Shock Trial,n=330,成人感染性休克,去甲肾上腺素剂量>5 μg/min持续>6小时)。体外实验发现白蛋白在20-30 g/L阈值浓度下抑制肝素结合蛋白(及凝血酶)诱导的内皮细胞通透性增加,但增加肾小管细胞白细胞介素-6释放。发生或恶化急性肾损伤的患者肝素结合蛋白与白蛋白比值(1.6 vs 0.89,p<0.001)和肝素结合蛋白水平(38.2 vs 20.8 ng/mL,p<0.001)显著高于无急性肾损伤患者。最高肝素结合蛋白与白蛋白比值(>3.05)、肝素结合蛋白四分位数(>69.8)及肝素结合蛋白>30 ng/mL与急性肾损伤发生或恶化显著相关(p<0.001),且与液体正平衡、炎症细胞因子、无急性肾损伤和无肾脏替代治疗生存天数、无血管加压药天数、无机械通气天数及28天死亡率显著相关。
要点
- 感染性休克患者中,发生或恶化急性肾损伤者肝素结合蛋白与白蛋白比值显著更高(1.6 vs 0.89,p<0.001),肝素结合蛋白水平也更高(38.2 vs 20.8 ng/mL,p<0.001)。
- 肝素结合蛋白>30 ng/mL和肝素结合蛋白与白蛋白比值>3.01(而非血清白蛋白)识别急性肾损伤高风险患者。
- 最高肝素结合蛋白与白蛋白比值(>3.05)、肝素结合蛋白四分位数(>69.8)与急性肾损伤发生或恶化显著相关(p<0.001),且经死亡竞争风险敏感性分析稳健。
- 肝素结合蛋白及肝素结合蛋白与白蛋白比值与液体正平衡(p<0.001)及关键炎症细胞因子直接相关。
- 体外实验中白蛋白在20-30 g/L阈值浓度下抑制肝素结合蛋白诱导的内皮细胞通透性增加,但增加肾小管细胞白细胞介素-6释放。
适用人群与场景
- 成人感染性休克患者,去甲肾上腺素剂量>5 μg/min持续>6小时(Vasopressin and Septic Shock Trial队列,n=330)。
- 体外实验使用人内皮细胞单层和人肾小管上皮细胞。
诊断标准与关键阈值
- 肝素结合蛋白>30 ng/mL和肝素结合蛋白与白蛋白比值>3.01识别急性肾损伤高风险(原文结论)。
- 最高肝素结合蛋白与白蛋白比值>3.05、肝素结合蛋白四分位数>69.8与急性肾损伤发生或恶化显著相关(p<0.001)。
研究设计与关键结果
- 研究类型:体外人内皮细胞和肾细胞模型及感染性休克观察队列(Vasopressin and Septic Shock Trial,多中心临床试验队列),样本量n=330。
- 体外:白蛋白在20-30 g/L阈值浓度下抑制肝素结合蛋白(及凝血酶)诱导的内皮细胞通透性增加,但增加肾小管细胞白细胞介素-6释放。
- 发生或恶化急性肾损伤患者肝素结合蛋白与白蛋白比值1.6 vs 无急性肾损伤患者0.89(p<0.001),肝素结合蛋白38.2 vs 20.8 ng/mL(p<0.001)。
- 最高肝素结合蛋白与白蛋白比值(>3.05)、肝素结合蛋白四分位数(>69.8)及肝素结合蛋白>30 ng/mL与急性肾损伤发生或恶化显著相关(p<0.001),未调整和调整分析均显著,且对死亡竞争结局敏感性分析稳健。
- 肝素结合蛋白及肝素结合蛋白与白蛋白比值与液体正平衡(p<0.001)及关键炎症细胞因子直接相关。
- 肝素结合蛋白与白蛋白比值和肝素结合蛋白(而非白蛋白)递增四分位数与无急性肾损伤和无肾脏替代治疗生存天数、无血管加压药天数、无机械通气天数及28天死亡率高度显著相关(p<0.001)。
证据类型、等级与局限
- 证据类型:体外实验及观察性队列研究(Vasopressin and Septic Shock Trial队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肝素结合蛋白>30 ng/mL和肝素结合蛋白与白蛋白比值>3.01(而非血清白蛋白)可识别感染性休克中急性肾损伤高风险患者。
- 体外实验提示白蛋白在20-30 g/L阈值浓度下可能抑制肝素结合蛋白诱导的内皮细胞通透性增加,但增加肾小管细胞白细胞介素-6释放。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Our objectives were to determine first whether albumin prevents heparin-binding protein-induced increased endothelial cell permeability and renal cell inflammation and second, whether a plasma heparin-binding protein-to-albumin ratio predicts risk of acute kidney injury, fluid balance, and plasma cytokine levels in septic shock.
DESIGN: In vitro human endothelial and renal cell model and observation cohort of septic shock.
SETTINGS: Research laboratory and multicenter clinical trial (Vasopressin and Septic Shock Trial).
PATIENTS: Adult septic shock (norepinephrine dose > 5 μg/min for > 6 hr).
INTERVENTIONS: In vitro: heparin-binding protein (or thrombin) was added with or without albumin to 1) human endothelial cell monolayers to assess permeability and 2) to human renal tubular epithelial cells to assess inflammation.
MEASUREMENTS AND MAIN RESULTS: Transendothelial electrical resistance-a marker of permeability-of human endothelial cells was measured using a voltohmmeter. We measured plasma heparin-binding protein-to-albumin ratio and a panel of cytokines in septic shock patients (n = 330) to define an heparin-binding protein-to-albumin ratio that predicts risk of acute kidney injury. Albumin inhibited heparin-binding protein (and thrombin-induced) increased endothelial cell permeability at a threshold concentration of 20-30 g/L but increased renal tubular cell interleukin-6 release. Patients who developed or had worsened acute kidney injury had significantly higher heparin-binding protein-to-albumin ratio (1.6 vs 0.89; p < 0.001) and heparin-binding protein (38.2 vs 20.8 ng/mL; p < 0.001) than patients without acute kidney injury. The highest heparin-binding protein-to-albumin ratio (> 3.05), heparin-binding protein quartiles (> 69.8), and heparin-binding protein > 30 ng/mL were significantly associated with development or worsening of acute kidney injury (p < 0.001) in unadjusted and adjusted analyses and were robust to sensitivity analyses for death as a competing outcome. Heparin-binding protein and heparin-binding protein-to-albumin ratio were directly associated with positive fluid balance (p < 0.001) and with key inflammatory cytokines. Increasing quartiles of heparin-binding protein-to-albumin ratio and heparin-binding protein (but not albumin) were highly significantly associated with days alive and free of acute kidney injury and renal replacement therapy (p < 0.001), vasopressors (p < 0.001), ventilation (p < 0.001), and with 28-day mortality.
CONCLUSIONS: Albumin inhibits heparin-binding protein-induced increased human endothelial cell permeability and heparin-binding protein greater than 30 ng/mL and heparin-binding protein-to-albumin ratio greater than 3.01-but not serum albumin-identified patients at increased risk for acute kidney injury in septic shock.
参考来源
- Fisher J, Linder A, Bentzer P, et al. Is Heparin-Binding Protein Inhibition a Mechanism of Albumin's Efficacy in Human Septic Shock? Crit Care Med. 2018. PMID: 29406419. doi:10.1097/CCM.0000000000002996
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。